Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib plus pemetrexed/carboplatin after progression on 1st or 2nd generation EGFR TKI in EGFR-mutated NSCLC
KCT0007524Phase 2Not yet recruiting
- Sponsor
- Yuhan
- Start
- Aug 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib, pemetrexed, carboplatin in EGFR-mutated non-small cell lung cancer, sponsored by Yuhan. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
lazertinibpemetrexedcarboplatin
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on KCT0007524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007524.